PERSPECTA

News from every angle

← Back to headlines

Antengene Receives Australian Approval for Phase I ATTRACT Study

Antengene has received clinical trial approval in Australia for its Phase I ATTRACT Study of ATG-201, targeting B cell-related autoimmune diseases.

25 Aug, 00:30 — 25 Aug, 00:30
PostShare

Sources

Showing 1 of 1 sources
taiwan-newsMostly Factual1d ago

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases - Taiwan News

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases  Taiwan News

Read full article →

Related Stories

France and Saudi Arabia Announce €6 Billion Dragon Ball Theme Park Project

26m ago

Serbia Announces New Direct Flights to Seville and Tenerife

26m ago

Coca-Cola Stock Splits: History and Future Prospects Explained

44m ago

Hotter July Inflation Data Keeps September Fed Rate Hike in Play

45m ago